BEACON2 is an international, multi arm, randomised Phase I/II platform trial for paediatric patients with relapsed or refractory high risk neuroblastoma. The study utilises an adaptive design to evaluate the safety and efficacy of various novel therapeutic combinations. The trial has two Tiers; Tier 1 is the main randomisation for treatment arms (two initially with potential for more). Tier 2 includes a smaller dose expansion/confirmation cohortfor more novel experimental treatment combinations. The primary objective is to test novel treatments again current best avilable treatment in relapsed neuroblastoma, and the secondary objective is to evaluate the safety of the regimes, anti-tumour response, longer term outcome and quality of life.